JP2019514347A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514347A5
JP2019514347A5 JP2018546004A JP2018546004A JP2019514347A5 JP 2019514347 A5 JP2019514347 A5 JP 2019514347A5 JP 2018546004 A JP2018546004 A JP 2018546004A JP 2018546004 A JP2018546004 A JP 2018546004A JP 2019514347 A5 JP2019514347 A5 JP 2019514347A5
Authority
JP
Japan
Prior art keywords
antibody
trem1
hvr
isolated antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546004A
Other languages
English (en)
Japanese (ja)
Other versions
JP7023853B2 (ja
JP2019514347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020745 external-priority patent/WO2017152102A2/en
Publication of JP2019514347A publication Critical patent/JP2019514347A/ja
Publication of JP2019514347A5 publication Critical patent/JP2019514347A5/ja
Priority to JP2022018475A priority Critical patent/JP7480197B2/ja
Application granted granted Critical
Publication of JP7023853B2 publication Critical patent/JP7023853B2/ja
Priority to JP2024070972A priority patent/JP2024119791A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546004A 2016-03-04 2017-03-03 抗trem1抗体及びその使用方法 Active JP7023853B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022018475A JP7480197B2 (ja) 2016-03-04 2022-02-09 抗trem1抗体及びその使用方法
JP2024070972A JP2024119791A (ja) 2016-03-04 2024-04-24 抗trem1抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662304018P 2016-03-04 2016-03-04
US62/304,018 2016-03-04
PCT/US2017/020745 WO2017152102A2 (en) 2016-03-04 2017-03-03 Anti-trem1 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022018475A Division JP7480197B2 (ja) 2016-03-04 2022-02-09 抗trem1抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019514347A JP2019514347A (ja) 2019-06-06
JP2019514347A5 true JP2019514347A5 (enExample) 2020-04-16
JP7023853B2 JP7023853B2 (ja) 2022-02-22

Family

ID=58348000

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018546004A Active JP7023853B2 (ja) 2016-03-04 2017-03-03 抗trem1抗体及びその使用方法
JP2022018475A Active JP7480197B2 (ja) 2016-03-04 2022-02-09 抗trem1抗体及びその使用方法
JP2024070972A Withdrawn JP2024119791A (ja) 2016-03-04 2024-04-24 抗trem1抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022018475A Active JP7480197B2 (ja) 2016-03-04 2022-02-09 抗trem1抗体及びその使用方法
JP2024070972A Withdrawn JP2024119791A (ja) 2016-03-04 2024-04-24 抗trem1抗体及びその使用方法

Country Status (4)

Country Link
US (3) US11472877B2 (enExample)
EP (1) EP3423493A2 (enExample)
JP (3) JP7023853B2 (enExample)
WO (1) WO2017152102A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3664845A4 (en) * 2017-08-08 2021-03-10 Pionyr Immunotherapeutics, Inc. COMPOSITIONS AND METHODS OF DEACTIVATION OF MYELOID CELLS EXPRESSING TREM1
US11975024B2 (en) 2017-12-19 2024-05-07 Musc Foundation For Research Development T regulatory (Treg) cell transplantation in osteogenesis imperfecta (OI)
JP7418332B2 (ja) * 2017-12-19 2024-01-19 スロゼン オペレーティング, インコーポレイテッド 抗フリズルド抗体及び使用方法
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN111886246B (zh) * 2017-12-29 2024-12-17 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
EP3852779A4 (en) 2018-09-17 2022-06-08 Abcuro, Inc. ANTI-KLRG1 ANTIBODIES
US12534532B2 (en) * 2018-10-26 2026-01-27 Crage Medical Co., Limited CLL1-targeting antibody and application thereof
MX2021009500A (es) * 2019-02-06 2021-09-08 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem1 y metodos relacionados.
CN110170053A (zh) * 2019-05-30 2019-08-27 澳门科技大学 组合物、其在制备肿瘤免疫治疗药物中的应用及药物组合物
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
EP3999541A1 (en) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
IL330191A (en) 2020-06-26 2026-08-01 Amgen Inc IL-10 mutants and their fusion proteins
CA3197465A1 (en) * 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
AR125732A1 (es) * 2021-05-03 2023-08-09 UCB Biopharma SRL Anticuerpos anti-trem1
CN117715940A (zh) * 2021-06-02 2024-03-15 伊诺特伦公司 抗trem-1抗体
MX2023015442A (es) * 2021-06-25 2024-03-12 Amgen Inc Tratamiento de la enfermedad cardiovascular con proteínas de unión a antígeno trem-1.
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
KR20260017009A (ko) 2023-04-21 2026-02-04 셀시우스 테라퓨틱스, 인코포레이티드 항-trem1 항체 제제, 조성물 및 이의 용도

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US8513185B2 (en) 2009-10-13 2013-08-20 Alexander B. Sigalov Inhibition of TREM receptor signaling with peptide variants
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
JP6411218B2 (ja) * 2012-02-15 2018-10-24 ノヴォ ノルディスク アー/エス 骨髄細胞で発現されるトリガー受容体1(trem−1)に結合し、それを遮断する抗体
US9550830B2 (en) * 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
MX385794B (es) 2012-09-07 2025-03-18 Inst Nat Sante Rech Med Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
MY205541A (en) * 2017-08-03 2024-10-25 Alector Llc Anti-cd33 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024119791A5 (enExample)
JP2021525082A5 (enExample)
JP7132232B2 (ja) Cd137及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
US11104745B2 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
JP2018525999A5 (enExample)
JP2018537956A5 (enExample)
JP2020528752A5 (enExample)
JP2020500540A5 (enExample)
JP2018518176A5 (enExample)
JP2019500014A5 (enExample)
EP3892634A1 (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
US20230365641A1 (en) Targeted cytokines and methods of use thereof
JP2021529520A5 (enExample)
JP2019500892A5 (enExample)
HRP20211980T1 (hr) Protutijela protiv sortilina i postupci njihove upotrebe
JP2018517401A5 (enExample)
Venkataramani et al. Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies
JP2020511947A5 (enExample)
JP2018516537A5 (enExample)
JP2020523038A5 (enExample)
CA3064298A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2022540620A (ja) 胸腺間質性リンパ球新生因子(tslp)受容体シグナル伝達に干渉する薬剤
JP7745556B2 (ja) Cd137結合分子及びその使用
JP2023543896A5 (enExample)
CA3247443A1 (en) Immunomodulatory Tri-Specific T-Lymphocyte Binding Fusion Proteins